FDA 510(k)

Magnus Neuromodulation System (MNS) with SAINT Technology, Model Number 1001K

K-Number: K220177 · 2022-09-01

Decision Date2022-09-01

Product CodeOBP

Advisory CommitteeNE

DecisionSubstantially Equivalent

Device Summary

Magnus Neuromodulation System (MNS) with SAINT Technology, Model Number 1001K is a medical device manufactured by Magnus Medical, Inc.. It received FDA 510(k) clearance on 2022-09-01 under approval number K220177. The device is classified under product code OBP. It was reviewed by the NE advisory panel. FDA Decision: Substantially Equivalent.

Frequently Asked Questions

What is the Magnus Neuromodulation System (MNS) with SAINT Technology, Model Number 1001K?

Magnus Neuromodulation System (MNS) with SAINT Technology, Model Number 1001K is a medical device that received FDA 510(k) clearance on 2022-09-01. It is manufactured by Magnus Medical, Inc.. The 510(k) number is K220177.

When was Magnus Neuromodulation System (MNS) with SAINT Technology, Model Number 1001K approved by the FDA?

Magnus Neuromodulation System (MNS) with SAINT Technology, Model Number 1001K received FDA 510(k) clearance on 2022-09-01, under approval number K220177.

What company makes Magnus Neuromodulation System (MNS) with SAINT Technology, Model Number 1001K?

Magnus Neuromodulation System (MNS) with SAINT Technology, Model Number 1001K is manufactured by Magnus Medical, Inc..

What is the FDA product code for Magnus Neuromodulation System (MNS) with SAINT Technology, Model Number 1001K?

The FDA product code for Magnus Neuromodulation System (MNS) with SAINT Technology, Model Number 1001K is OBP.

Related Clinical Trials

NCT01174108 Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells RECRUITING NCT03053791 Deep Brain Stimulation in Patients With Incomplete Spinal Cord Injury for Improvement of Gait RECRUITING NCT07611721 Evaluate the Performance of the Dexcom G7 Continuous Glucose Monitoring (CGM) System in Critically Ill Patients Undergoing Major Abdominal Surgery and Solid Organ Transplantation Which Require Blood Glucose Monitoring for Intensive Insulin Therapy. RECRUITING NCT07430293 Hybrid Closed-Loop Insulin Delivery After Pancreatectomy RECRUITING NCT07607457 Development and Evaluation of the Effectiveness of Patient Gowns for Patients Undergoing Abdominal Surgery NOT_YET_RECRUITING NCT06690658 Self-Practicing Upper Body Exercises With a Robotic Trainer System RECRUITING

Related PubMed Literature

PMID: 41987469 [Progress and Prospects of Ultrasound Brain-Computer Interface Medical Devices Technology]. Zhongguo yi liao qi xie za zhi = Chinese journal of medical instrumentation (2026) PMID: 41915420 Analysis Model for Infant Incubator Adverse Events Using Retrieval-Augmented Generation Combined With Dual-Adapter Fine-Tuning: Development and Evaluation Study. JMIR medical informatics (2026) PMID: 41887630 Capacity building for ethical use of artificial intelligence in health: protocol for a scoping review of training initiatives and gaps in Africa. BMJ open (2026) PMID: 41054198 Relevant domains for health technology assessment of medical device reimbursement in Brazil's unified health system: a survey and Delphi panel study on stakeholder preferences. International journal of technology assessment in health care (2025)

Related Devices (Code: OBP)

K160309Neurosoft TMSTeleemg, LLC K161519NeuroStar TMS Therapy SystemNeuronetics, Inc. K160703NeuroStar TMS Therapy SystemNeuronetics, Inc. K173441Neurosoft TMS (also CloudTMS)Teleemg, LLC K171902Nexstim Navigated Brain Therapy (NBT) System 2Nexstim Plc K172667MagVita TMS Therapy w/MagPro R20Tonica Elektronik A/S

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.